


Concurrent *JAK2* mutation and isolated del(5q) associated with marrow fibrosis and small hypo/monolobated megakaryocytes

Rosemarie Tremblay-LeMay and Hong Chang, University of Toronto



A 68-year-old woman of Asian descent presented with fatigue and anemia requiring blood transfusion. There was no splenomegaly. The blood work revealed hemoglobin, 59 g/L; mean corpuscular volume, 103 fL; absolute neutrophil count, $2.3 \times 10^9/L$; platelets, $238 \times 10^9/L$; and lactate dehydrogenase, 246 U/L. Occasional teardrop cells and rare pseudo-Pelger neutrophils were found in the blood smear. The bone marrow aspirate was a dry tap. The biopsy showed a hypercellular marrow with proliferation of small hypo/monolobated megakaryocytes forming clusters (panel A; original magnification $\times 40$, hematoxylin and eosin stain) that stained positive for CD61 (panel B; original magnification $\times 40$, CD61 stain). CD34⁺ blasts were $< 5\%$. There was increased reticulin fibrosis (marrow fibrosis [MF] 2/3) (panel C; original magnification $\times 20$, reticulin stain). Molecular studies

detected *JAK2* V617F mutation with 29% allele burden; conventional cytogenetics demonstrated an isolated 5q deletion in 4 of 20 metaphases [46,XX, del(5)(q22q35)], confirmed by interphase fluorescence in situ hybridization in 25% of nuclei.

Myelodysplastic syndrome with isolated del(5q) is characterized by distinctive hypo/monolobated megakaryocytes. Concurrent *JAK2* mutation has been described in 5% of cases, but significant MF (≥ 2) was not reported. Isolated del(5q) in primary myelofibrosis (PMF) is extremely rare. The megakaryocyte morphology typical of PMF was absent in this case. Whether there are 2 independent clones or 1 clone expressing both abnormalities remains to be determined. Nevertheless, this patient could potentially benefit from lenalidomide.